AFFYMAX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0007 USD | 0.00% |
|
-66.67% | +16.67% |
Financials (USD)
| Sales 2012 | 94.37M | Sales 2013 | 1.37M | Capitalization | 29.24M |
|---|---|---|---|---|---|
| Net income 2012 | -93M | Net income 2013 | -14M | EV / Sales 2012 | 6.75 x |
| Net cash position 2012 | 69.14M | Net cash position 2013 | 5.6M | EV / Sales 2013 | 17.3 x |
| P/E ratio 2012 |
-7.39
x | P/E ratio 2013 |
-2.03
x | Employees | 2 |
| Yield 2012 * |
-
| Yield 2013 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 week | -66.67% | ||
| 6 months | +40.00% | ||
| Current year | +16.67% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.00
1 year
0.000.04
3 years
0.000.10
5 years
0.000.26
10 years
0.000.74
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 0.0007 | 0.00% | 3,000 |
| 24-04-25 | 0.0007 | -66.67% | 515 |
Delayed Quote OTC Markets, April 29, 2024 at 10:27 am EDT
More quotes
Affymax, Inc. is a biopharmaceutical company. The Companyâs product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Companyâs product, OMONTYS.
| 1st Jan change | Capi. | |
|---|---|---|
| +16.67% | 26.24K | |
| +1.77% | 42.86B | |
| +43.62% | 41.36B | |
| +12.24% | 42.74B | |
| -8.83% | 27.68B | |
| +7.44% | 25.15B | |
| -23.01% | 18.63B | |
| +30.56% | 12.37B | |
| -1.82% | 11.92B | |
| +8.35% | 11.21B |
- Stock Market
- Equities
- AFFY Stock
